tirzepatide patent news Drug Patents containing Lilly releases Zepbound® (tirzepatide) single-dose

At TrimRx, we understand that these logistical details matter just as much as the clinical ones

On the other hand, the risks of HHF (HR 0.93, 95% CI 0.831.04 with GLP-1RAs and HR 0.69, 95% CI 0.610.79 with SGLT2is) and composite kidney outcomes excluding macroalbuminuria (HR 0.92, 95% CI 0.801.06 with GLP-1RAs and HR 0.55, 95% CI 0.480.64 with SGLT2is) significantly reduced with SGLT2is only

Obesity is a chronic, systemic disease driven by excess adiposity that can cause severe organ dysfunction and lifethreatening complications (for example, stroke, cardiovascular disease, type 2 diabetes, depression, and certain cancers) [1,2]

Water is the medium in which most chemical reactions, including degradation, occur

The medication neither increased nor decreased UTI risk in any meaningful way